Charles Schwab
SYRS

Charles Schwab’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Charles Schwab’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,699
Closed -$152K – 3666
2022
Q1 		$152K Sell
12,699
-1,574
-11% -$28.2K ﹤0.01% 3351
2021
Q4 		$466K Sell
14,273
-6
-0% -$243 ﹤0.01% 3172
2021
Q3 		$639K Sell
14,279
-24,901
-64% -$1.22M ﹤0.01% 3058
2021
Q2 		$2.14M Buy
39,180
+2,863
+8% +$169K ﹤0.01% 2697
2021
Q1 		$2.72M Buy
36,317
+12,022
+49% +$1.25M ﹤0.01% 2563
2020
Q4 		$2.64M Sell
24,295
-16
-0.1% -$1.46K ﹤0.01% 2522
2020
Q3 		$2.15M Sell
24,311
-778
-3% -$88.4K ﹤0.01% 2472
2020
Q2 		$2.67M Buy
25,089
+4,572
+22% +$410K ﹤0.01% 2313
2020
Q1 		$1.22M Sell
20,517
-18
-0.1% -$1.22K ﹤0.01% 2442
2019
Q4 		$1.42M Buy
20,535
+626
+3% +$38K ﹤0.01% 2505
2019
Q3 		$2.07M Sell
19,909
-488
-2% -$46.1K ﹤0.01% 2364
2019
Q2 		$1.89M Buy
20,397
+9,108
+81% +$634K ﹤0.01% 2388
2019
Q1 		$1.03M Sell
11,289
-1,414
-11% -$98.5K ﹤0.01% 2541
2018
Q4 		$708K Sell
12,703
-203
-2% -$15.4K ﹤0.01% 2645
2018
Q3 		$1.54M Buy
12,906
+1,697
+15% +$197K ﹤0.01% 2504
2018
Q2 		$1.15M Buy
11,209
+3,535
+46% +$438K ﹤0.01% 2550
2018
Q1 		$997K Buy
7,674
+3,331
+77% +$364K ﹤0.01% 2514
2017
Q4 		$423K Buy
4,343
+172
+4% +$23.1K ﹤0.01% 2771
2017
Q3 		$614K Buy
4,171
+2,041
+96% +$384K ﹤0.01% 2659
2017
Q2 		$343K Buy
+2,130
New +$335K ﹤0.01% 2817

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Charles Schwab's SYRS Position: Q2 2022 in Review

Charles Schwab sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2022, closing a stake of 12,699 shares — an estimated $152K sold.

Charles Schwab first reported a position in SYRS in Q2 2017 and held it in 20 quarters. The position peaked at $2.72M in Q1 2021. 67 funds tracked by Wall St. Rank hold SYRS as of Q2 2022.

  • Charles Schwab reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Charles Schwab sold 12,699 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $152K.
  • Charles Schwab first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 20 quarters.
  • Charles Schwab's Syros Pharmaceuticals, Inc. Common Stock position peaked at $2.72M in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Charles Schwab's 13F filing for Q2 2022, filed 15 Aug 2022.